Executive functioning during full and partial remission (positive and negative symptomatic remission) of schizophrenia

Schizophrenia Research

Volumn 142, Issue 1-3, 2012, Pages 122-128

  Braw, Yoram ^a,b   Benozio, Avi ^c,d   Levkovitz, Yechiel ^a,c  

^a SHALVATA MENTAL HEALTH CENTER   (Israel)

^b ARIEL UNIVERSITY   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

CANTAB; Cognition; Executive functioning; Schizophrenia; Symptomatic remission

Indexed keywords

ADULT; AGED; ARTICLE; ATTENTION; CONTROLLED STUDY; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; FUNCTIONAL STATUS; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL TASK; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; REMISSION; SCHIZOPHRENIA; WORKING MEMORY;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ATTENTION; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84869863703     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.10.011     Document Type: Article

References (58)

1. Alvarez J.A., Emory E. Executive function and the frontal lobes: a meta-analytic review. Neuropsychol. Rev. 2006, 16(1):17-42.
2. Andreasen N.C., Olsen S. Negative v positive schizophrenia. Definition and validation. Arch. Gen. Psychiatry 1982, 39(7):789-794.
3. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162(3):441-449.
4. APA Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC. 4 ed.
5. Banich M.T. Executive function: the search for an integrated account. Curr. Dir. Psychol. Sci. 2009, 18:89-94.
6. Braw Y., Aviram S., Bloch Y., Levkovitz Y. The effect of age on frontal lobe cognitive functions of unmedicated depressed patients. J. Affect. Disord. 2011, 129:342-347.
7. Brissos S., Dias V.V., Carita A.I., Martinez-Aran A. Quality of life in bipolar type I disorder and schizophrenia in remission: clinical and neurocognitive correlates. Psychiatry Res. 2008, 160(1):55-62.
8. Brissos S., Dias V.V., Balanza-Martinez V., Carita A.I., Figueira M.L. Symptomatic remission in schizophrenia patients: relationship with social functioning, quality of life, and neurocognitive performance. Schizophr. Res. 2011, 129(2-3):133-136.
9. Cassidy C.M., Norman R., Manchanda R., Schmitz N., Malla A. Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2years. Schizophr. Bull. 2010, 36(5):1001-1008.
10. Ceaser A.E., Goldberg T.E., Egan M.F., McMahon R.P., Weinberger D.R., Gold J.M. Set-shifting ability and schizophrenia: a marker of clinical illness or an intermediate phenotype?. Biol. Psychiatry 2008, 64(9):782-788.
11. Cohen J. Statistical power analyses for the behavioural sciences 1988, Academic Press, New York. 2 ed.
12. Cohen J. A power primer. Psychol. Bull. 1992, 112(1):155-159.
13. De Hert M., van Winkel R., Wampers M., Kane J., van Os J., Peuskens J. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr. Res. 2007, 92(1-3):68-73.
14. De Luca C.R., Wood S.J., Anderson V., Buchanan J.A., Proffitt T.M., Mahony K., Pantelis C. Normative data from the CANTAB. I: development of executive function over the lifespan. J. Clin. Exp. Neuropsychol. 2003, 25(2):242-254.
15. Dominguez Mde G., Viechtbauer W., Simons C.J., van Os J., Krabbendam L. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychol. Bull. 2009, 135(1):157-171.
16. Eling P., Derckx K., Maes R. On the historical and conceptual background of the Wisconsin Card Sorting Test. Brain Cogn. 2008, 67(3):247-253.
17. Gorwood P., Peuskens J. Setting new standards in schizophrenia outcomes: symptomatic remission 3 years before versus after the Andreasen criteria. Eur. Psychiatry 2012, 27(3):170-175.
18. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26(1):119-136.
19. Green M.F., Kern R.S., Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 2004, 72(1):41-51.
20. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fargas A., Rodriguez M.J., Rele R., Orta J., Kharbeng A., Araya S., Gervin M., Alonso J., Mavreas V., Lavrentzou E., Liontos N., Gregor K., Jones P.B. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand. Suppl. 2003, (416):16-23.
21. Harvey P.D., Bellack A.S. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?. Schizophr. Bull. 2009, 35(2):300-306.
22. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12(3):426-445.
23. Hilti C.C., Delko T., Orosz A.T., Thomann K., Ludewig S., Geyer M.A., Vollenweider F.X., Feldon J., Cattapan-Ludewig K. Sustained attention and planning deficits but intact attentional set-shifting in neuroleptic-naive first-episode schizophrenia patients. Neuropsychobiology 2010, 61(2):79-86.
24. Hofer A., Bodner T., Kaufmann A., Kemmler G., Mattarei U., Pfaffenberger N.M., Rettenbacher M.A., Trebo E., Yalcin N., Fleischhacker W.W. Symptomatic remission and neurocognitive functioning in patients with schizophrenia. Psychol. Med. 2011, 41:2131-2139.
25. Hutton S.B., Puri B.K., Duncan L.J., Robbins T.W., Barnes T.R., Joyce E.M. Executive function in first-episode schizophrenia. Psychol. Med. 1998, 28(2):463-473.
26. Joyce E.M., Roiser J.P. Cognitive heterogeneity in schizophrenia. Curr. Opin. Psychiatry 2007, 20(3):268-272.
27. Joyce E., Hutton S., Mutsatsa S., Gibbins H., Webb E., Paul S., Robbins T., Barnes T. Executive dysfunction in first-episode schizophrenia and relationship to duration of untreated psychosis: the West London Study. Br. J. Psychiatry 2002, (Suppl. 43):s38-s44.
28. Joyce E.M., Hutton S.B., Mutsatsa S.H., Barnes T.R. Cognitive heterogeneity in first-episode schizophrenia. Br. J. Psychiatry 2005, 187:516-522.
29. Jurado M.B., Rosselli M. The elusive nature of executive functions: a review of our current understanding. Neuropsychol. Rev. 2007, 17(3):213-233.
30. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
31. Keefe R.S., Fenton W.S. How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophr. Bull. 2007, 33(4):912-920.
32. Kopelowicz A., Liberman R.P., Ventura J., Zarate R., Mintz J. Neurocognitive correlates of recovery from schizophrenia. Psychol. Med. 2005, 35(8):1165-1173.
33. Krishnadas R., Moore B.P., Nayak A., Patel R.R. Relationship of cognitive function in patients with schizophrenia in remission to disability: a cross-sectional study in an Indian sample. Ann. Gen. Psychiatry 2007, 6:19.
34. Kurtz M.M. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr. Res. 2005, 74(1):15-26.
35. Lasser R.A., Nasrallah H., Helldin L., Peuskens J., Kane J., Docherty J., Tronco A.T. Remission in schizophrenia: applying recent consensus criteria to refine the concept. Schizophr. Res. 2007, 96(1-3):223-231.
36. Levaux M.N., Potvin S., Sepehry A.A., Sablier J., Mendrek A., Stip E. Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. Eur. Psychiatry 2007, 22(2):104-115.
37. Li C.T., Su T.P., Chou Y.H., Lee Y.C., Liu M.E., Ku H.L., Shan I.K., Bai Y.M. Symptomatic resolution among Chinese patients with schizophrenia and associated factors. J. Formos. Med. Assoc. 2010, 109(5):378-388.
38. Luciana M. Practitioner review: computerized assessment of neuropsychological function in children: clinical and research applications of the Cambridge Neuropsychological Testing Automated Battery (CANTAB). J. Child Psychol. Psychiatry 2003, 44(5):649-663.
39. Matza L.S., Buchanan R., Purdon S., Brewster-Jordan J., Zhao Y., Revicki D.A. Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment. Schizophr. Bull. 2006, 32(4):666-678.
40. McCabe D.P., Roediger H.L., McDaniel M.A., Balota D.A., Hambrick D.Z. The relationship between working memory capacity and executive functioning: evidence for a common executive attention construct. Neuropsychology 2010, 24(2):222-243.
41. Medalia A., Choi J. Cognitive remediation in schizophrenia. Neuropsychol. Rev. 2009, 19(3):353-364.
42. Miyake A., Friedman N.P., Emerson M.J., Witzki A.H., Howerter A., Wager T.D. The unity and diversity of executive functions and their contributions to complex "Frontal Lobe" tasks: a latent variable analysis. Cogn. Psychol. 2000, 41(1):49-100.
43. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004, 72(1):29-39.
44. Palmer B.W., Dawes S.E., Heaton R.K. What do we know about neuropsychological aspects of schizophrenia?. Neuropsychol. Rev. 2009, 19(3):365-384.
45. Pantelis C., Wood S.J., Proffitt T.M., Testa R., Mahony K., Brewer W.J., Buchanan J.A., Velakoulis D., McGorry P.D. Attentional set-shifting ability in first-episode and established schizophrenia: relationship to working memory. Schizophr. Res. 2009, 112(1-3):104-113.
46. Penades R., Catalan R., Puig O., Masana G., Pujol N., Navarro V., Guarch J., Gasto C. Executive function needs to be targeted to improve social functioning with Cognitive Remediation Therapy (CRT) in schizophrenia. Psychiatry Res. 2010, 177(1-2):41-45.
47. Sahakian B.J., Owen A.M. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J. R. Soc. Med. 1992, 85(7):399-402.
48. San L., Ciudad A., Alvarez E., Bobes J., Gilaberte I. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. Eur. Psychiatry 2007, 22(8):490-498.
49. Sarter M., Givens B., Bruno J.P. The cognitive neuroscience of sustained attention: where top-down meets bottom-up. Brain Res. Brain Res. Rev. 2001, 35(2):146-160. (Research Support, U.S. Gov't, P.H.S. Review).
50. Shallice T. Specific impairments of planning. Philos. Trans. R. Soc. Lond. B Biol. Sci 1982, 298(1089):199-209.
51. Smith E.E., Jonides J. Storage and executive processes in the frontal lobes. Science 1999, 283(5408):1657-1661.
52. Spitzer R.L., Williams J.B., Gibbon M. Structured clinical interview for DSM-III-R: non-patient version (SCID-NP) 1989, New-York State Psychiatric Institute, New-York.
53. Spitzer R.L., Williams J.B., Gibbon M., First M.B. The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch. Gen. Psychiatry 1992, 49(8):624-629.
54. Ventura J., Hellemann G.S., Thames A.D., Koellner V., Nuechterlein K.H. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr. Res. 2009, 113(2-3):189-199.
55. Wunderink L., Nienhuis F.J., Sytema S., Wiersma D. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr. Bull. 2007, 33(3):792-796.
56. Wykes T., Huddy V., Cellard C., McGurk S.R., Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psychiatry 2011, 168(5):472-485.
57. Yen C.F., Cheng C.P., Huang C.F., Ko C.H., Yen J.Y., Chang Y.P., Chen C.S. Relationship between psychosocial adjustment and executive function in patients with bipolar disorder and schizophrenia in remission: the mediating and moderating effects of insight. Bipolar Disord. 2009, 11(2):190-197.
58. Yun da Y., Hwang S.S., Kim Y., Lee Y.H., Kim Y.S., Jung H.Y. Impairments in executive functioning in patients with remitted and non-remitted schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35(4):1148-1154.